Merck & Co.
AWARDS
NEWS
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 9, 2021.
Merck and Ridgeback Biotherapeutics announced preliminary results from Ridgeback’s Phase IIa trial of molnupiravir in COVID-19.
The company notes that this decision has no effect on other indications for Keytruda.
On Thursday, the company said the U.S. Food and Drug Administration wants to see additional data beyond the Phase III study announced last year.
Merck said the acquisition adds a pipeline of drug candidates that target a broad range of autoimmune diseases.
Agilent is one of seven health care companies to make the fourth annual list of 100 companies compiled by the publication.
JOBS
IN THE PRESS